Royalty Pharma (RPRX) Stock Revenue Strength Masks Thin Earnings

Royalty Pharma stock barely budged after earnings, up just 0.5% to about US$57.75, yet the quarter itself was anything but flat. The market is treating this like a routine update, while the headline is a sharp squeeze in profitability. Net income excluding extra items came in at US$18 million on US$674 million of revenue, a fraction of recent quarters.

For a company that sells long duration royalty cash flows, that disconnect between a rich P/E, strong cash metrics and thin reported earnings is where sentiment will be tested next.

Is Royalty Pharma’s rich P/E multiple pointing to genuine upside or setting up investors for disappointment on thin reported earnings, despite strong cash metrics and a high DCF fair value estimate? See how the current share price lines up against our valuation analysis for Royalty Pharma

Q2 2026 Earnings Summary

• Revenue (Q2 2026 vs Q2 2025): US$674 million vs. US$578.665 million (higher revenue year on year)
• Net Income (Excl. Extra Items, Q2 2026 vs Q2 2025): US$18 million vs. US$30.176 million (lower net income year on year)
• Basic EPS (Q2 2026 vs Q2 2025): US$0.0406 vs. US$0.0713 (lower earnings per share year on year)
• Portfolio Receipts Growth (Q2 2026): Royalty Pharma reported 14% growth in recurring royalty receipts and 6% growth in total portfolio receipts to US$773 million, with total portfolio cash flow at US$736 million and about 95% cash conversion

Prefer clear visuals over another wall of earnings tables and footnotes? See Royalty Pharma’s full valuation picture laid out in simple charts and one clean dashboard in our company report for Royalty Pharma.

Royalty Pharma’s Bull Case Hangs On Cash, Not EPS

The bullish story around Royalty Pharma hinges on two claims. First, that internalization and expense control will lift margins and earnings per share. Second, that a scalable royalty model and active deal flow will keep cash generation growing ahead of traditional earnings. Q2 results hit key cost milestones. Operating and professional expenses were 4.8% of portfolio receipts, which is already better than the 5.5% to 6.5% range guided for 2026. That supports the idea that structural cost cuts are feeding through, even though net income excluding extra items was only US$18 million and basic EPS fell year on year.

On the growth side, recurring royalty receipts grew 14% and portfolio receipts reached US$773 million, with about 95% cash conversion. Combined with the cliramitug royalty deal and US$877 million deployed in H1 2026, the company is hitting the origination and cash flow milestones that bullish investors expect.

Reveal where the surface looks calm, but the multi year models start to disagree on Royalty Pharma’s path from here. Access the full revenue, EPS and cash flow analyst estimates for Royalty Pharma.

Royalty Pharma Bears Still Point To Earnings Fragility

The core bearish worry around Royalty Pharma is that reported earnings will not keep up with the story on cash and that rising headwinds on key drugs and regulation will eventually show up in weaker profitability. This quarter hands the bears some clear misses. Net income excluding extra items was only US$18 million despite US$674 million of revenue and strong portfolio receipts, so the gap between earnings and cash remains wide. Basic EPS fell year on year while management needed to raise 2026 guidance partly to reassure investors that royalty growth can offset loss of exclusivity pressures, biosimilars and lower milestones. Regulatory and product specific risks are now explicitly embedded in guidance rather than hypothetical. Taken together, the cash engine is working, but this print does not yet disprove concerns that accounting earnings remain thin against a complex risk backdrop.

After thin earnings, rising debt, insider selling and tighter guidance, review whether these are early warnings or isolated issues. Scan our risk analysis for Royalty Pharma which shows 3 important warning signs

Take Control Of Your Next Move

If the gap between Royalty Pharma’s cash engine and thin reported earnings has your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch how the story evolves before picking an entry point. Once you are invested, keep your decisions focused with the Portfolio Command Center that cuts through noise and highlights only the key developments that matter for your holdings. For a broader view on what other investors see in Royalty Pharma and similar stocks, tap into the collective insight of the Community. By spotting potential catalysts and risks earlier, you give yourself a better chance to stay ahead of the market rather than reacting to it late.

Seeking Alternatives Before The Crowd Does

Some of the sharpest breakouts start quietly, while momentum builds under the radar for now. Spot fresh setups before the crowd, while it matters, and get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com